Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity
© Morgan and Hill; licensee BioMed Central Ltd. 2005
Received: 06 July 2004
Accepted: 08 February 2005
Published: 08 February 2005
Breast cancer cells frequently metastasize to the skeleton and induce extensive bone destruction. Cancer cells produce proteinases, including matrix metalloproteinases (MMPs) and the plasminogen activator system (PAS) which promote invasion of extracellular matrices, but whether these proteinases degrade bone matrix is unclear. To characterize the role that breast cancer cell proteinases play in bone degradation we compared the effects of three human breast cancer cell lines, MDA-MB-231, ZR-75-1 and MCF-7 with those of a normal breast epithelial cell line, HME. The cell lines were cultured atop radiolabelled matrices of either mineralized or non-mineralized bone or type I collagen, the principal organic constituent of bone.
The 3 breast cancer cell lines all produced significant degradation of the 3 collagenous extracellular matrices (ECMs) whilst the normal breast cell line was without effect. Breast cancer cells displayed an absolute requirement for serum to dissolve collagen. Degradation of collagen was abolished in plasminogen-depleted serum and could be restored by the addition of exogenous plasminogen. Localization of plasmin activity to the cell surface was critical for the degradation process as aprotinin, but not α2 antiplasmin, prevented collagen dissolution. During ECM degradation breast cancer cell lines expressed urokinase-type plasminogen activator (u-PA) and uPA receptor, and MMPs-1, -3, -9,-13, and -14. The normal breast epithelial cell line expressed low levels of MMPs-1, and -3, uPA and uPA receptor. Inhibitors of both the PAS (aprotinin and PA inhibitor-1) and MMPs (CT1166 and tisue inhibitor of metalloproteinase) blocked collagen degradation, demonstrating the requirement of both plasminogen activation and MMP activity for degradation. The activation of MMP-13 in human breast cancer cells was prevented by plasminogen activator inhibitor-1 but not by tissue inhibitor of metalloproteinase-1, suggesting that plasmin activates MMP-13 directly.
These data demonstrate that breast cancer cells dissolve type I collagen and that there is an absolute requirement for plasminogen activation and MMP activity in the degradation process.
Breast cancer is the most frequent cancer in the female population of industrialized countries. Metastasis of breast cancer cells to the skeleton occur in >70% of patients with progressive disease, resulting in debilitating symptoms such as severe bone pain, fractures, hypercalcaemia and spinal cord or nerve compressions due to extensive bone loss and tumour cell growth and expansion. Such bone loss occurs as a result of increased bone matrix resorption but the mechanisms by which cancer cells mediate this increased degradation have not been fully elucidated. Obviously, tumour expansion in bone requires the removal of the extracellular matrix (ECM) that is particularly abundant in bone. Cancer cells express matrix metalloproteinases (MMPs) and the plasminogen activator system (PAS) [1–3] and their levels of expression increase with progression of the tumour.
The matrix metalloproteinases (MMPs) constitute a large family of structurally related matrix degrading proteases that have pivotal roles in development, tissue remodelling, and cancer [4–6]. The gene family of MMPs includes the interstitial collagenases (MMPs-1 and -13), gelatinase A (MMP-2), gelatinase B (MMP-9), the stromelysins (MMPs-3, 10 and 11) and the membrane type-matrix metalloproteinases (MT-MMPs 14,15,16,17, 24 and 25) . The MMPs have the combined ability to degrade the major components of the ECM including type I collagen, the principal organic constituent of bone .
The PAS comprises: tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), their inhibitors, and receptors. T-PA is thought to be more important in fibrinolysis, due to its fibrin binding capacity, whilst u-PA, especially when it is bound to its specific cell surface receptor (u-PAR), is thought to be involved in tissue remodelling and cell migration processes . Whereas uPA alone recognizes a narrow range of substrates, the enzyme can catalyze the conversion of the circulating zymogen, plasminogen to plasmin. Plasmin, in turn, is a broad- spectrum proteinase that can directly degrade multiple ECM targets and can also cooperate with other ECM-degrading enzymes including members of the MMP gene family. Regulation of the PA/plasmin system is achieved mainly via plasminogen activator inhibitor (PAI) type-1 and type-2 and by agents that stimulate bone resorption, e.g. parathyroid hormone (PTH) and interleukin (IL)-1 .
To date, emphasis has focused on the ability of breast cancer cells to stimulate the formation and activity of osteoclasts, the cell primarily responsible for bone resorption under physiological conditions. The ability of osteoclasts to degrade bone lies in their ability to secrete protons and specialized collagenolytic proteinases, the cysteine proteinases in the acidic microenvironment that underlies osteoclasts during bone resorption .
Experimental studies showing that increased expression of MMPs and the PAS is associated with increased cellular invasion in vivo support the idea that they play an important role in metastasis of tumour cells [10, 11]. Obviously tumour expansion in bone necessitates the removal of the ECM that is particularly abundant and resistant to degradation. Synthetic inhibitors of MMPs have been developed and two recent reports on their use on in vivo breast cancer metastasis to bone show promise when given as a preventive treatment to mice [12, 13]. However, the role of MMPs and the PAS in mediating breast tumour bone collagen dissolution has not been addressed.
We have therefore assessed the ability of three human breast cancer cell lines, MDA-MB-231 (MDA-231), ZR-75-1 and MCF-7 to degrade bone collagen in vitro using matrix degradation assays and compared their effects with those of a normal breast epithelial cell line, HME. We correlated the degradation activity of the breast cancer cells with their expression of MMPs and the PAS and we assessed the ability of group-selective proteinase inhibitors to prevent degradation of the organic aspect of bone by breast cancer cells.
Type I collagen degradation
The ability of the cancer cells to degrade the type I collagen is consistent with the expression of proteolytic activity. However, the midpoint melting temperature of reconstituted firbrillar type I collagen (47°C) is lower than that of authentic type I collagen in tissues (55°C to 60°C) . Because the proteinase resistance of type I collagen can be compromised at temperatures within 10°C of that at which the helix reversibly unfolds , reconstituted fibrillar collagen may provide a less resistant substrate to proteolytic activity. Hence to determine whether breast cancer cell mediated degradation of type I collagen could be extended to a more physiological system, cancer cells were cultured on bone matrix as described below.
Bone matrix degradation by breast cancer cells
The described sequential gene expression of differentiating osteoblasts  was verified in MC3T3-E1 cell cultures so that non-mineralized matrix production was prepared after collagen production had commenced but before mineralization started. Mineralization of the matrices was confirmed by von Kossa staining (not shown).
Expression of mRNA for MMPs and the PAS by breast tumour cells
MMP and uPA production by breast cancer cells
Production of uPA by Breast Cancer Cells
uPA (U/1 × 105 cells/24 h)
Roles of MMPs and PAS in breast cancer cell mediated bone degradation
The data presented in this paper clearly demonstrate that human breast carcinoma cell lines have the capacity to degrade the organic aspect of bone matrix in vitro, and there is a dependency on the PA system for the cell-mediated collagen degradation. Furthermore, we have shown that plasmin associated with the cell surface is responsible for activating the fibrillar collagenase, MMP-13.
The ECM in our experiments was produced by MC3T3-E1 mouse calvarial-derived cells. These cells display osteoblast-like characteristics, providing a suitable model of osteogenesis analogous to in vivo bone formation . The bone nature is evident from the appearance of mineralization, resulting in the production of a solid sheet of mineralized matrix. Our evidence showing that breast cancer cells degrade bone matrix is in agreement with that of Eilon and Mundy  who reported that MCF-7 cells were capable of degrading the organic aspect of devitalized murine bone explants in vitro. More recently it has been demonstrated that prostate cancer cells and melanoma cells directly degrade mineralized bone matrix and that the degradation was reduced by generalized inhibition of MMP activity [19, 20].
Whereas the induction of MMPs in TGFβ stimulated breast cancer cells that are actively engaged in tumour osteolysis has not been examined previously, this growth factor has been reported to increase the expression of MMPs-1, -3 and -9 . In our study TGFβ induced a complex MMP expression profile that included MMPs-1, -3, -9 -13, and -14 as the principle products. Furthermore, MMPs are able to release and activate TGFβ, a very abundant bone matrix-bound factor .
The fact that breast cancer cells degraded the non-mineralized bone matrix to a greater extent than the mineralized substrate, suggests that access of the matrix degrading proteinases to the organic phase of the matrix may have been restricted by the mineralized phase.
This investigation has demonstrated a significant difference in the ability of breast cancer cells and normal breast epithelial cells to degrade the organic aspect of bone matrix in vitro. Variations in the profile and amounts of proteinases expressed by the different cell lines may be responsible. Since the MMP inhibitors used in this study (CT1166 and TIMP-1) inhibit the activities of all MMPs, except the membrane-type MMPs in the case of TIMP-1, we cannot identify the contribution of individual MMP members to bone matrix degradation. However, our demonstration of a direct requirement of plasmin in the activation of proMMP-13 suggests that this fibrillar collagenase may play a prominent role in the degradative activity of breast cancer cells. However, the possibility of other known MMPs also being involved in plasminogen-dependent collagenolysis by breast cancer cells cannot be excluded. The participation of the membrane-type MMPs such as MMP-14, -15 and -16 is improbable due to the ability of TIMP-1 to effectively block collagen dissolution by breast cancer cells. MMP-2 and – 8 were not expressed in detectable amounts by breast cancer cells, as assessed by RT-PCR. The existence of very small, but functionally important, amounts of MMP-2 or – 8 however cannot be excluded unequivocally by the expression studies. MMP-1 is expressed by the human breast cancer cells in this study and may contribute to plasmin-dependent fibrillar collagen dissolution.
Currently, little is known with regard to the physiological mechanisms by which MMPs undergo activation in intact cell systems . However, a primary function of the uPA-uPAR couple is to focus the processing of the plasminogen zymogen to active plasmin on the cell surface. It has recently been demonstrated that binding of u-PA to its receptor increases pro-MMP-2,-9  and -13  activation, and that in the absence of cells, plasmin not only fails to activate pro-MMPs, but rapidly degrades them . This would explain why interfering with only one element, plasmin or MMP activity, has such powerful biological effects. It should be stressed, however, that few of the cascades or activities have been unequivocally documented in intact cell systems. Nonetheless, because MMP-specific inhibitors are not yet available, the individual role of each of the cell-derived MMPs awaits the use of interventions based on RNA inhibition.
The increased bone resorption that accompanies breast cancer cell infiltration of bone may arise as a result of (1) breast cancer cells stimulating osteoblast and osteoclast activity and (2) the production by breast cancer cells of proteinases that participate in degrading the organic aspect of bone matrix which would also facilitate the access of osteoclasts to the underlying mineralized matrix.
Even if tumour-derived MMPs do not directly digest mineralized matrix, they may participate in osteolysis via a mechanism that is analogous to a known osteoblast function. It is believed that all endosteal surfaces are covered with a layer of nonmineralized matrix. In areas of bone formation, this layer is called osteoid and it is easily observed in stained sections . Evidence is accumulating that degradation of this layer must occur before the attachment of osteoclasts to the underlying mineralized matrix . In normal remodelling, digestion of this layer is apparently accomplished by MMPs produced by osteoblasts [25–27]. It is conceivable that breast cancer cells in bone adopt this osteoblast function; thus, the possibility that MMPs produced by cancer cells enhance osteoclastic degradation by prior removal of the overlying unmineralized layer. Furthermore, removal of this layer may be partially responsible for the recruitment and activity of osteoclasts due to the release of osteoclast attractants/stimulants. Bone resorption by osteoclasts is augmented experimentally by coating mineralized matrix with collagenase-cleaved collagen fragments . As nonmineralized matrix is degraded, osteoclasts may be exposed to extracellular proteins, such as fibronectin, vitronectin, osteopontin or other cryptic epitopes. Osteoclasts bind to these proteins via integrins a process that may enhance bone resorption .
In conclusion, we have shown that breast cancer cells can degrade the organic aspect of bone matrix in contrast to non-tumourogenic breast epithelial cells. There is an absolute requirement for both the PA system and MMPs in the degradation process.
Materials and methods
The MMP inhibitor CT-1166 was a generous gift from Dr A Docherty, Celltech (Slough, UK). The PAS inhibitor aprotinin, plasminogen and TGFβ were purchased from Sigma. The human mammary epithelial cell (HMEC) line, Mammary Epithelial Basal Medium (MEBM), insulin, hydrocortisone, gentamicin/amphotericin-B and Bovine Pituitary Extract (BPE) were purchased from Clonetics (Walkersville, MD, USA). Human breast tumour cell lines MDA-231, ZR-75-1 and MCF-7 were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA). Gelatinase-A, TIMP-1 and polyclonal sheep antibodies to human MMP-1, -2,- 3, -9 and -13 were gifts from Dr J Reynolds, Strangeways Research Laboratory, Cambridge, UK. Neutralizing mAbs against human uPA or human uPAR were from American Diagnostica, Greenwich, CT, USA.
Cell lines were cultured in 75-cm2 plastic tissue culture flasks (Costar Corning, Cambridge, MA, USA) as follows: ZR-75-1, MDA-231, MCF-7 and MC-3T3-E1 in α-MEM and HME cells in MEBM medium. All media were supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin (Sigma Chemical Co.). Cultures were maintained at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide and subcultured every third day.
Type I collagen degradation assay
14C-labelled collagen films were prepared as described previously . Breast cells were seeded into collagen coated 16 mm tissue culture wells at a density of 1 × 105 /well. After 4 h incubation at 37°C in MEM supplemented with 10% FCS, the cells were washed twice with phosphate buffered saline (PBS) to remove residual FCS, and incubated for 24 h with 1 ml/well of serum-free MEM with or without the indicated concentrations of plasminogen, TGFβ and the proteinase inhibitors to be tested. At the end of the culture period the media were centrifuged (15 min, 1200 × g) to remove any collagen fibrils, and radioactivity released during collagen degradation quantified by liquid scintillation counting. Residual collagen was digested with bacterial collagenase (50 μg/ml) and assayed for radioactivity. Collagenolysis was expressed as radioactivity released from the films as a percentage of the total ± SEM.
Formation of 3H-labelled, non-mineralized and mineralized bone matrix
The murine calvarial-derived MC3T3-E1 is a well characterized osteoblast culture system providing a suitable model of osteogenesis analogous to in vivo bone formation . The cultures were maintained at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide. Culture medium was changed on the first day after seeding and then every 72 h. The cells were split after 7–9 days in culture, before they reached confluence, and plated at a density of 1 × 104 cells/well on collagen-coated 24-well plates (Becton Dickinson, MA, USA). After 4–5 days, when the cultures had reached confluence and the formation of an ECM had started, fresh medium was added containing 1 μCi/ml 3H amino acid mixture for 7 days (Amersham International, Aylesbury, UK) to create a non-mineralized radiolabelled ECM. In order to create a mineralized bone matrix, the medium was supplemented with 10 mM β-glycerol phosphate and the cells cultured for 14 days and the radiolabelled medium changed every 3 days. Unincorporated 3H-radiolabelled amino acids were washed from the remaining ECM using 2 water washes and 75% (v/v) ethanol. The matrices were dried and stored at -20°C until use.
Von Kossa staining for mineralization
Mineralization of matrices was determined by von Kossa staining. The matrices were rinsed with cold PBS and fixed in 10% neutral buffered formalin for 15 min, rinsed with distilled water and left in distilled water for 15 min. Matrices were stained with 2.5 % silver nitrate solution for 30 min at room temperature. The silver nitrate was removed and matrices were rinsed with distilled water before the addition of sodium carbonate formaldehyde for 5 min. After rinsing, the matrices were counterstained with toluidine blue, rinsed with tap water and air dried.
Bone matrix degradation assay
Breast cancer cells (105 /16 mm culture well) were seeded onto the bone matrix as for the type I collagen degradation assay. After 4 h incubation at 37°C in MEM supplemented with 10% FCS, the cells were washed twice with phosphate buffered saline (PBS) to remove residual FCS, and incubated for 24 h with 1 ml/well of serum-free MEM with or without the indicated concentrations of plasminogen, TGFβ and the proteinase inhibitors that were tested. After 24 h incubation, the media were removed and the extent of degraded 3H-radiolabelled matrix released into the medium was determined by liquid scintillation counting. The remaining matrix was degraded as for the type I collagen assay and matrix degradation expressed as above.
PCR and RT-PCR
Confluent breast tumour cells were stimulated with TGFβ (10-10 M) in serum-free medium for 24 h. For PCR analysis, oligonucleotide primers were synthesized based on the published sequences for 14 MMPs (i.e., MMP-1, -2, -3, -7,-8,-9,-10, -11, -12, -13,-14,-15, -16, and -17) . t-PA, u-PA and, u-PAR oligonucleotides were designed using Designer PCR (Research Genetics, AL, USA) and primers purchased from Life Technologies Ltd. The housekeeping gene GAPDH was used as a positive control for the RT-PCR methodology.
Enzymes and buffers for the reverse transcriptase and PCR reactions were obtained from Perkin Elmer (CA, USA). Reverse transcriptase reactions were done according to the manufacturer's protocol using 1 μg of total RNA collected from untreated or TGF-β treated breast cells. PCR reactions were performed in an automated DNA thermal cycler (Perkin Elmer) for 25 cycles of denaturation (95°C, 1 min), annealing (variable time and temperature) and polymerisation (60°C, variable time). Amplification of the house-keeping gene, G3PDH mRNA (35 cycles), provided an internal control for the efficiency of the RT-PCR process. RT-PCR products were analyzed against molecular weight standards (pBR322 HaeIII digest) on a 2.5% agarose gel stained with ethidium bromide, electrophoresed in 0.5× TBE buffer at 100 V for 90 minutes. Gels were examined under ultraviolet light and photographed. The authenticity of the PCR products was verified by sequencing .
Western Blot analysis
To identify MMP proteins and uPA present in breast cell conditioned medium, Western blot analysis was performed using their specific antibodies as previously described . Briefly, samples were separated by 8.5% SDS-PAGE, transblotted on to PVDF membranes (Millipore Corp., MA, USA) and immunoblotted with polyclonal sheep antiserum to MMPs or polyclonal goat antiserum to uPA and secondary peroxidase-conjugated anti-sheep / anti-goat antibodies. Labelled proteins were detected with ECL detection solution and exposed to autoradiographic film (Hyperfilm ECL, Amersham International, UK).
Assay of collagenase activity
To measure collagenase activity, TGFβ (10-10 M)-stimulated breast cells were cultured in the presence/absence of 2 ug/ml of human plasminogen for 24 h. Collagenase activity was measured by the degradation of fluorescein isothiocyanate (FITC)-labelled type I collagen using type I activity assay kits. One unit of these activities degrades 1 μg of collagen per min at 37°C.
Cells were plated in 6-well trays and grown to near confluence, the medium was removed, and the cells were washed and incubated with 2 ml of serum-free medium for 24 hr. The medium was collected, centrifuged, and frozen until assayed. The cells were lysed in 300 ul of 0.1 M Tris (pH 8.1) and 0.1% Triton X-100. The u-PA (10 ul of conditioned medium and 10 μg of cell protein) was assayed as previously described  using plasminogen and S2251, the chromogenic substrate for plasmin.
Differences between control and treatment groups were determined by the Mann Whitney U-test.
- Baker EA, Stephenson TJ, Reed MW, Brown NJ: Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol. 2002, 55: 300-304. 10.1136/mp.55.5.300.PubMed CentralView ArticlePubMedGoogle Scholar
- Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen Activators, Tissue Degradation, and Cancer. Adv Cancer Res. 1985, 44: 139-266.View ArticlePubMedGoogle Scholar
- Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A Matrix Metalloproteinase Expressed on the Surface of Invasive Tumour Cells. Nature. 1994, 370: 61-65. 10.1038/370061a0.View ArticlePubMedGoogle Scholar
- Birkedal-Hansen H: Proteolytic remodelling of the extracellular matrix. Curr Opin Cell Biol. 1995, 7: 728-735. 10.1016/0955-0674(95)80116-2.View ArticlePubMedGoogle Scholar
- McCawley LJ, Matrisian LM: Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol. 2001, 13: 534-540. 10.1016/S0955-0674(00)00248-9.View ArticlePubMedGoogle Scholar
- Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I: Matrix metalloproteinases in arthritic disease. Arthritis Res. 2002, 4: S39-S49. 10.1186/ar572.PubMed CentralView ArticlePubMedGoogle Scholar
- Sprengers ED, Kluft C: Plasminogen Activator Inhibitors. Blood. 1987, 69: 381-387.PubMedGoogle Scholar
- Hamilton JA, Lingelbach S, Partridge NC, Martin TJ: Regulation of Plasminogen Activator Production by Bone-Resorbing Hormones in Normal and Malignant Osteoblasts. Endocrinology. 1985, 116: 2186-2191.View ArticlePubMedGoogle Scholar
- Delaisse J-M, Vaes G: Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption. Biology and Physiology of the Osteoclast. Edited by: Rifkin BR, Gay CV. 1992, CRC Press, Boca Raton, 289-314.Google Scholar
- Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, Lund LR, Danø K, Ruiter DJ, Verheijen JH: Metastatic Behaviour of Human Melanoma Cell Lines in Nude Mice Correlates with Urokinase-Type Plasminogen Activator, its Type-1 Inhibitor, and Urokinase-mediated Matrix Degradation. J Cell Biol. 1991, 115: 191-199. 10.1083/jcb.115.1.191.View ArticlePubMedGoogle Scholar
- Sato H, Seiki M: Membrane-Type Matrix Metalloproteinases (MT-MMPs) in Tumour Metastasis. J Biochem. 1996, 119: 209-215.View ArticlePubMedGoogle Scholar
- Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W: A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer. 2001, 37: 106-113. 10.1016/S0959-8049(00)00363-4.View ArticlePubMedGoogle Scholar
- Weber MH, Lee J, Orr FW: The effect of Neovastat (AE-941) on an experimental metastatic bone tumour model. Int J Oncol. 2002, 20: 299-303.PubMedGoogle Scholar
- Deutsch DG, Mertz ET: Plasminogen:purification from human plasma by affinity chromatography. Science. 1970, 170: 1095-1096.View ArticlePubMedGoogle Scholar
- Quarles LD, Yohay D, Lever L, Caton R, Wenstrup RJ: Distinctive proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res. 1992, 7: 683-692.View ArticlePubMedGoogle Scholar
- Netzel-Arnett S, Mitola DJ, Yamada S, Chrysovergis K, Holmbeck K, Birkedal-Hansen H, Bugge TH: Collagen Dissolution by Keratinocytes Requires Cell Surface Plasminogen Activation and Matrix Metalloproteinase Activity. J Biol Chem. 2002, 277: 45154-45161. 10.1074/jbc.M206354200.View ArticlePubMedGoogle Scholar
- Sudo H, Kodama H, Amagai Y, Yamamoto S, Kasai S: In vitro differentiation and calcification in a new clonal osteogenic cell line derived from new born mouse calvaria. J Cell Biol. 1983, 96: 191-198. 10.1083/jcb.96.1.191.View ArticlePubMedGoogle Scholar
- Eilon G, Mundy G: Direct resorption of bone by human breast cancer cells in vitro. Nature. 1978, 276: 726-728.View ArticlePubMedGoogle Scholar
- Sanchez-Sweatman OH, Lee J, Orr FW, Singh G: Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur J Cancer. 1997, 33: 918-25. 10.1016/S0959-8049(97)00513-3.View ArticlePubMedGoogle Scholar
- Sanchez-Sweatman OH, Orr FW, Singh G: Human Metastatic Prostate PC3 Cell Lines Degrade Bone Using Matrix Metalloproteinases. Invasion Metastasis. 1998, 18: 297-305. 10.1159/000024522.View ArticlePubMedGoogle Scholar
- Duivenvoorden WC, Hirte HW, Singh G: Transforming growth factor β1 acts an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 1999, 17: 27-34. 10.1023/A:1026404227624.View ArticlePubMedGoogle Scholar
- Yu Q, Stamenkovic I: Cell-surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumour invasion and angiogenesis. Genes Dev. 2000, 14: 163-176.PubMed CentralPubMedGoogle Scholar
- Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P: Control of type IV collagenase activity by components of the urokinase-Plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 1997, 16: 2319-2332. 10.1093/emboj/16.9.2319.PubMed CentralView ArticlePubMedGoogle Scholar
- Fornasier VL: Osteoid: an ultrastructural study. Hum Pathol. 1977, 8: 243-254.View ArticlePubMedGoogle Scholar
- Chambers TJ, Fuller K: Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic bone resorption. J Cell Sci. 1985, 76: 155-165.PubMedGoogle Scholar
- Meikle MC, Bord S, Hembry RM, Compston J, Croucher PI, Reynolds JJ: Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines. J Cell Sci. 1992, 103: 1093-9.PubMedGoogle Scholar
- Hill PA, Murphy G, Docherty AJP, Hembry RM, Millican TA, Reynolds JJ, Meikle MC: The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci. 1994, 107: 3055-3064.PubMedGoogle Scholar
- Holiday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL: Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem. 1994, 272: 22053-8. 10.1074/jbc.272.35.22053.View ArticleGoogle Scholar
- Rodan SB, Rodan GA: Integrin function in osteoclasts. J Endocrinol. 1997, 154 (Suppl): S47-56.PubMedGoogle Scholar
- Hill PA, Docherty AJP, Bottomley KMK, O'Connell JP, Morphy JR, Reynolds JJ, Meikle MC: Inhibition of Bone Resorption In Vitro by Selective Inhibitors of Gelatinase and Collagenase. Biochem J. 1995, 308: 167-175.PubMed CentralView ArticlePubMedGoogle Scholar
- Pei D, Weiss SJ: Transmembrane deletion mutants of the membrane-type matrix metalloproteinase-1 activate progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem. 1996, 271: 9135-9140. 10.1074/jbc.271.21.12639.View ArticlePubMedGoogle Scholar
- Mira-y-Lopez R, Ossowski L: Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumour responsiveness. Cancer Res. 1987, 47: 3558-3564.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.